You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
FINGOLIMOD SANDOZ is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.
Size 3 capsule with white opaque body and bright yellow opaque cap; radial imprint with black ink, 'FTY 0.5 mg' on cap and two radial bands imprinted on the body with yellow ink.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
FINGOLIMOD SANDOZ is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.
Size 3 capsule with white opaque body and bright yellow opaque cap; radial imprint with black ink, 'FTY 0.5 mg' on cap and two radial bands imprinted on the body with yellow ink.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on September, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
FINGOLIMOD SANDOZ is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.
Size 3 capsule with white opaque body and bright yellow opaque cap; radial imprint with black ink, 'FTY 0.5 mg' on cap and two radial bands imprinted on the body with yellow ink.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
FINGOLIMOD SANDOZ is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.
Ivory opaque (body and cap), size 3, with black radial imprint FTY 0.25 mg on cap and black radial band on body containing white to almost white powder
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
FINGOLIMOD SANDOZ is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.
Ivory opaque (body and cap), size 3, with black radial imprint FTY 0.25 mg on cap and black radial band on body containing white to almost white powder
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
